BioSpace News Archive

New software will leverage the VisualDx expert system for space travel

The Company also announced the pricing of warrants to purchase up to 42,860,000 shares of common stock at an exercise price of $0.50 per share and with a term of 5 years commencing on the date of issuance.

About 20% of children in the U.S. are frequently hungry while nearly 50 million Americans do not get enough to eat.

National Health IT Solutions Provider Adds Accomplished Leader

Cook provides this data to encourage further collaboration with researchers to benefit patients with peripheral arterial disease.

TAU BIO-LOGIC CORP. announced today that in collaboration with the UK-based group LifeArc, it has successfully humanized a monoclonal antibody (TBL-100) that targets C-terminally truncated tau (tauC3). TAU BIO-LOGIC is developing TBL-100 for the treatment of Alzheimer’s disease (AD) and Progressive Supranuclear Palsy (PSP).

Assistance for UnitedHealthcare plan participants whose access to care or prescriptions needs may have been affected

Physician Introduces Breakthrough AccuTite: One-Time Procedure, 15 Minute Treatment Time, Local Anesthesia, Minimal Downtime, Permanent Results

AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, announced today that Health Canada has approved SKYRIZI™ (risankizumab) for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

The Longest Running Cannabis Terpene Laboratory Offers New Formulation and Delivery Applications for Terpenes That Satisfy Any Application a Manufacturer Could Conceive